AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Genital Warts (Condylomata Acuminata): Podophyllotoxin is applied topically to external genital warts. It works by interfering with the growth of wart cells, leading to their destruction. This treatment is often preferred for small, external warts and is usually applied directly to the affected area.
Antimitotic Activity: Podophyllotoxin is classified as a cytotoxic agent due to its antimitotic properties. It inhibits cell division (mitosis) by binding to tubulin, a protein involved in the formation of microtubules necessary for cell division. By disrupting this process, podophyllotoxin causes the death of rapidly dividing cells, such as those in genital warts.
Local Skin Reactions: Common side effects of podophyllotoxin treatment include local skin reactions at the application site, such as redness, burning, itching, and pain. These reactions are usually mild to moderate in severity and resolve after discontinuation of treatment.
Contraindications: Podophyllotoxin should not be used during pregnancy due to the risk of systemic absorption and potential harm to the fetus. It should also be avoided in patients with known hypersensitivity to podophyllotoxin or any of its components.
Effectiveness: Podophyllotoxin is generally considered effective in the treatment of genital warts, with studies demonstrating high rates of wart clearance. However, it may require multiple treatment sessions over several weeks for optimal results.
Follow-Up: Patients treated with podophyllotoxin should be monitored regularly by a healthcare provider to assess treatment response and manage any adverse effects. Follow-up visits may be necessary to ensure complete resolution of warts and to address any recurrence.
Patient Education: Patients using podophyllotoxin should be educated about proper application techniques, potential side effects, and the importance of compliance with treatment instructions. They should also be advised to avoid sexual contact while lesions are present and during treatment.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 1.4 | 0.3 | 3.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0 | 0 |
| Allergies | 0.9 | 0.6 | 0.5 |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alzheimer's disease | 1.6 | 1.8 | -0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0 | 0 |
| Ankylosing spondylitis | 0.6 | 0.9 | -0.5 |
| Anorexia Nervosa | 1.7 | -1.7 | |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 2.2 | 0.9 | 1.44 |
| Atherosclerosis | 0.9 | 0.9 | 0 |
| Atrial fibrillation | 0.9 | 0.3 | 2 |
| Autism | 2.2 | 2.1 | 0.05 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 0.6 | 0.8 | -0.33 |
| Brain Trauma | 0.8 | -0.8 | |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.6 | 0.5 | 0.2 |
| Carcinoma | 1.3 | 0.6 | 1.17 |
| Celiac Disease | 1 | 0.9 | 0.11 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 1.3 | 0.5 | 1.6 |
| Chronic Kidney Disease | 0.6 | 0.8 | -0.33 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 1.1 | -2.67 |
| Chronic Urticaria (Hives) | 0.3 | -0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 0.8 | 0.8 | 0 |
| Colorectal Cancer | 2.4 | 0.8 | 2 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 1.4 | -1.4 | |
| COVID-19 | 1.6 | 1.9 | -0.19 |
| Crohn's Disease | 2.4 | 2.1 | 0.14 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 1 | 0.8 | 0.25 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 3.8 | 2.4 | 0.58 |
| Eczema | 0.3 | 0.3 | 0 |
| Endometriosis | 0.3 | 1.1 | -2.67 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.9 | 0.3 | 2 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.8 | 0.6 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 1.3 | 1.1 | 0.18 |
| gallstone disease (gsd) | 0.3 | 0.8 | -1.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.3 | 1.33 |
| Generalized anxiety disorder | 0.9 | 0.8 | 0.13 |
| Gout | 0.3 | 0 | 0 |
| Graves' disease | 0.3 | 0.8 | -1.67 |
| Gulf War Syndrome | 0.3 | -0.3 | |
| Halitosis | 0.7 | 0.7 | |
| Hashimoto's thyroiditis | 1.4 | 0.6 | 1.33 |
| Heart Failure | 0.5 | 0.6 | -0.2 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0 | 0 |
| hyperglycemia | 0.6 | 0.3 | 1 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 0.6 | 1.5 | -1.5 |
| Hypothyroidism | 0 | 0.3 | 0 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.9 | 0.9 | 0 |
| Inflammatory Bowel Disease | 1.4 | 2.1 | -0.5 |
| Insomnia | 0.3 | 1.1 | -2.67 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 1.3 | 1.4 | -0.08 |
| ischemic stroke | 0.3 | 0.8 | -1.67 |
| Liver Cirrhosis | 2 | 1.7 | 0.18 |
| Long COVID | 1.4 | 1.8 | -0.29 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0 | 0 | |
| Mast Cell Issues / mastitis | 0.1 | 0.1 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.5 | 0.3 | 0.67 |
| Menopause | 0.6 | -0.6 | |
| Metabolic Syndrome | 2 | 2 | 0 |
| Mood Disorders | 3.9 | 1.9 | 1.05 |
| multiple chemical sensitivity [MCS] | 0 | 0 | |
| Multiple Sclerosis | 0.8 | 1.2 | -0.5 |
| Multiple system atrophy (MSA) | 0 | 0 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.3 | 1.4 | -3.67 |
| Neuropathy (all types) | 0.3 | 0.8 | -1.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 1.4 | 0.21 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 2.6 | 3.5 | -0.35 |
| obsessive-compulsive disorder | 1.2 | 0.6 | 1 |
| Osteoarthritis | 0.6 | 0.3 | 1 |
| Osteoporosis | 1.1 | 0.3 | 2.67 |
| pancreatic cancer | 0.4 | 0.4 | |
| Parkinson's Disease | 2.3 | 1.9 | 0.21 |
| Polycystic ovary syndrome | 1.4 | 1.1 | 0.27 |
| primary biliary cholangitis | 0.6 | -0.6 | |
| Primary sclerosing cholangitis | 0.6 | 0.6 | |
| Psoriasis | 0.3 | 0.9 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 1.7 | -0.13 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.7 | 1.1 | 0.55 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.3 | 0.6 | -1 |
| Sleep Apnea | 0.6 | 1.1 | -0.83 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 1.1 | 1 | 0.1 |
| Systemic Lupus Erythematosus | 1.4 | 1.2 | 0.17 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0 | 0.3 | 0 |
| Type 1 Diabetes | 0.6 | 1.1 | -0.83 |
| Type 2 Diabetes | 2 | 1.7 | 0.18 |
| Ulcerative colitis | 1 | 1.7 | -0.7 |
| Unhealthy Ageing | 1.3 | 0.8 | 0.63 |
| Vitiligo | 0.9 | 0 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
